Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (149)	5/21/1998 10:02:00 PM
From: Cytotekk	Read Replies (1) \| Respond to of 178

The management is sitting and waiting for insurance carriers to reimburse at any rate in order to avoid million dollar wrongful death lawsuits. Unfortunately for all the cytology technologies, we have more than two new approaches to an old problem and the public is very ignorant of this area of laboratory medicine. If people really think that sending thousands of slides off to a papnet site/machine that doesnt even rank probability of atypia and relies on the same old tech judgement, is acceptable; or that charging $10.00/pap for $1.50 worth of materials and a modified old technology cytospin machine are the cutting edge solution to misdiagnosed cervical cancer, than it is anybodies guess as to who wins the war of cytotech stocks. Neopath has the best solution to existing problems but they are crummy marketers and salespeople. We had to insist 4 times, in person, to get the company to get some data together that could be presented to insurance carriers to justify reimbursement. The last meeting we had, the same old ignorant, tired salesman announced that they had HIRED someone to complete the data/proposal/cost analysis we had been asking for. I havent received it yet and it has been six months since we last talked. Obviously they think the they are so wonderful that the product will sell itself. Ask Apple Computer or Beta video how well that approach works. I back this technology, it makes the most sense. None of the competition or NPTH is perfect. I guess I am dreaming to expect the public to understand the advantages/disadvantages of any of the cytology technology. Stock holders bailed when the stock did not take a jump after official FDA approval of limited primary screening. They expected to get back to the high $20s again. Unfortunately, npth had already become yesterdays cold mashed potatoes. I still believe npth will become the dominant cyto lab technology but it is going to be slow going with the present management and sales force. They may even do an Apple and commit virtual suicide. I will hope for the best and wait and see. Cytc does not cut it for so many reasons, and I have noticed that their recent announcement did nothing for their stock price. I would rather see 1 million cells to evaluate than 300,000. NPTH has hooked up with a company who will use thinprep, mono cell layer over an entire 50mm slide, not just a circle in the middle of a slide. A much more thorough method of CA detection, many more cells to be examined. I will be calling the company soon and asking my usual politically incorrect questions. I will report my findings soon.